IRADIMED CORPORATION Financials IRADIMED CORPORATION
Equities
IRMD
US46266A1097
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.65 USD | -2.35% |
|
+6.67% | -8.09% |
| May. 02 | Transcript : IRADIMED CORPORATION, Q1 2024 Earnings Call, May 02, 2024 | |
| May. 02 | Earnings Flash (IRMD) IRADIMED CORPORATION Posts Q1 Revenue $17.6M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 268.5 | 279.7 | 570.3 | 355.5 | 598.4 | 566.1 | - | - |
| Enterprise Value (EV) 1 | 268.5 | 279.7 | 570.3 | 355.5 | 598.4 | 566.1 | 566.1 | 566.1 |
| P/E ratio | 30 x | 207 x | 62.4 x | 27.7 x | 35.2 x | 32.2 x | 27.7 x | 21.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.97 x | 8.82 x | 13.6 x | 6.67 x | 9.13 x | 7.8 x | 6.97 x | 5.72 x |
| EV / Revenue | 6.97 x | 8.82 x | 13.6 x | 6.67 x | 9.13 x | 7.8 x | 6.97 x | 5.72 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,485 | 12,270 | 12,342 | 12,566 | 12,606 | 12,664 | - | - |
| Reference price 2 | 23.38 | 22.80 | 46.21 | 28.29 | 47.47 | 44.70 | 44.70 | 44.70 |
| Announcement Date | 2/6/20 | 2/4/21 | 2/4/22 | 2/2/23 | 2/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 38.52 | 31.72 | 41.81 | 53.3 | 65.56 | 72.54 | 81.17 | 98.9 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | 8.647 | -0.7561 | 9.818 | 15.63 | 20.04 | 20.55 | 25.28 | 34.62 |
| Operating Margin | 22.45% | -2.38% | 23.48% | 29.32% | 30.56% | 28.33% | 31.15% | 35% |
| Earnings before Tax (EBT) 1 | 9.043 | -0.6169 | 9.836 | 16.18 | 21.74 | 22.55 | 26.54 | 35.13 |
| Net income 1 | 9.631 | 1.369 | 9.325 | 12.83 | 17.19 | 17.79 | 20.85 | 27.4 |
| Net margin | 25% | 4.32% | 22.3% | 24.06% | 26.22% | 24.52% | 25.69% | 27.7% |
| EPS 2 | 0.7800 | 0.1100 | 0.7400 | 1.020 | 1.350 | 1.390 | 1.615 | 2.120 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/4/21 | 2/4/22 | 2/2/23 | 2/8/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.87 | 12.31 | 12.72 | 13.41 | 14.86 | 15.48 | 16.13 | 16.5 | 17.45 | 17.6 | 17.65 | 17.7 | 19.6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 3.11 | 3.075 | 4.167 | 4.132 | 4.254 | 4.007 | 4.963 | 5.905 | 5.16 | 4.748 | 4.86 | 5.089 | 5.88 |
| Operating Margin | 26.19% | 24.98% | 32.75% | 30.82% | 28.62% | 25.89% | 30.77% | 35.78% | 29.57% | 26.98% | 27.54% | 28.76% | 30% |
| Earnings before Tax (EBT) 1 | 3.114 | 3.06 | 4.18 | 4.237 | 4.704 | 4.35 | 5.298 | 6.409 | 5.682 | 5.244 | 5.36 | 5.589 | 6.33 |
| Net income 1 | 3.893 | 2.487 | 3.241 | 3.427 | 3.673 | 3.406 | 4.18 | 5.067 | 4.54 | 4.137 | 4.228 | 4.418 | 5.024 |
| Net margin | 32.79% | 20.2% | 25.48% | 25.56% | 24.71% | 22.01% | 25.91% | 30.7% | 26.01% | 23.51% | 23.95% | 24.96% | 25.64% |
| EPS 2 | 0.3100 | 0.2000 | 0.2600 | 0.2700 | 0.2900 | 0.2700 | 0.3300 | 0.4000 | 0.3600 | 0.3200 | 0.3300 | 0.3400 | 0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/4/22 | 4/29/22 | 7/29/22 | 11/3/22 | 2/2/23 | 5/4/23 | 8/3/23 | 11/3/23 | 2/8/24 | 5/2/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/4/21 | 2/4/22 | 2/2/23 | 2/8/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
44.7
USD
Average target price
62.5
USD
Spread / Average Target
+39.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.84% | 566M | |
| +73.37% | 12.39B | |
| -17.09% | 8.08B | |
| +16.88% | 7.25B | |
| +3.57% | 5.86B | |
| +11.77% | 5.35B | |
| +29.65% | 4.63B | |
| -17.74% | 4.19B | |
| -35.26% | 2.44B | |
| +3.09% | 2.07B |
- Stock Market
- Equities
- IRMD Stock
- Financials IRADIMED CORPORATION